Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | TP53 | P04637 | 5/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | RAD52 | P43351 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27253863 | 0.89 | DHFR (0.50) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL24355432 | 0.87 | PDPK1 (0.57) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL29756065 | 0.87 | PDPK1 (0.57) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL29361482 | 0.83 | POLB (0.63) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL879558 | 0.83 | POLB (0.63) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL13335780 | 0.81 | PDE4A (0.57) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL24355108 | 0.80 | PDE4A (0.45) | PDE4APDE4D | |
| SCHEMBL26069641 | 0.80 | POLB (0.49) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL11404500 | 0.80 | POLB (0.59) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL29642054 | 0.80 | POLB (0.59) | POLBKMT2ALMNAGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | claimed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | claimed |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4225383-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| WO-2022076917-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2009016387-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE | CIPLA LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | POLB 2591/4885KMT2A 834/4885LMNA 3538/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | POLB 719/4885KMT2A 1071/4885LMNA 1074/4885 |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | MKI67, MYC, CCNK | POLB 1167/4885KMT2A 3192/4885LMNA 2637/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | POLB 191/4885KMT2A 92/4885LMNA 742/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | POLB 2232/4885KMT2A 2987/4885LMNA 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.